SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

SciSparc Ltd.

SciSparc Ltd. (NASDAQ: SPRC) is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol (CBD): SCI-110 (formerly THX-110) for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; SCI-160 (formerly THX-160) for the treatment of pain; and SCI-210 (formerly THX-210) for the treatment of autism spectrum disorder and epilepsy.

SciSparc

SciSparc today announced the publication of a manuscript that teaches the uses of its proprietary drug candidate SCI-110 for Tourette Syndrome (TS). The study was conducted at the Department of Psychiatry, and the Child Study Center at Yale University in New Haven, Connecticut, USA. The manuscript titled "A Pilot Study of a Therapeutic Combination of Δ9-tetrahydracannabinol and Palmitoylethanolamide for Adults with Tourette Syndrome," was published in the Journal of Neuropsychiatry and Clinical Neurosciences. https://prn.to/3aTubUg

SciSparc today announced it has been awarded two patents from the Australian Patent Office and one from the Japanese Patent Office concerning the proprietary compounds and methods underlying the Company's core technologies. Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented, "I am pleased that the Australian and Japanese patent offices have recognized the uniqueness of our pharmaceutical compounds. This is important for the long-term value of any associated products as the Patents establish claims that safeguard the core technologies at the heart of our product pipeline." https://prn.to/3BUvXjL

Our rebrand reflects SciSparc's plans to develop proprietary compounds that capitalize on the biochemistry of receptors that specialize in modulating the CNS to create therapeutics that mitigate the adverse symptoms associated with CNS disorders https://prn.to/3AP6jfC

NASDAQ:SPRC

SciSparc Ltd

Last Close

1.26

03/05 20:00

Market Cap

11.28M

Beta: -

Volume Today

53.77K

Avg: 1.06M

PE Ratio

−6.39

PFCF: −0.69

locale

market

industry

website

crunchbase

linkedin

ipo date

Earnings

Earnings per Share (Estimate*)

Revenue (Estimate*)

Metrics